Aurinia Pharmaceuticals has strong Lupkynis sales, robust pipeline, and financial health drive growth. See why we rate AUPH ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

In a finding set to change the way disease is monitored, Chandra Mohan, an international expert and pioneer in lupus research ...

Roche has received FDA approval for its antibody treatment Gazyva to be used in combination with standard therapy for adults with active lupus ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...

Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro ...

The FDA has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, Genentech said.